Nursing interventions in adverse reactions in cancer patients using immunotherapy: A scoping review
DOI:
https://doi.org/10.33448/rsd-v10i7.16871Keywords:
Immunotherapy; Neoplasm; Oncology nursing.Abstract
This study aims to map the scientific evidence on nursing interventions related to the management of adverse reactions in adult oncology patients using immunotherapy in the outpatient setting. This is a scoping review, based on the JBI methodology. The population of adult and elderly oncology patients using immunotherapy was used as a strategy, in the concept of nursing interventions in the administration and control of adverse reactions of injectable immunotherapies, with the outpatient setting (PCC) as the context, in line with the JBI guidelines for scoping review. Twenty-three articles were selected, with publications between 2005 and 2020. Three aspects were evidenced for discussion: Nursing interventions in relation to patient/family health education using immunotherapeutics, nursing interventions related to the application of immunotherapeutics to the patient and related interventions adverse reactions after the application of immunotherapeutics. It is evident how much it is necessary the physical examination performed by the nurse and pharmacological knowledge about immunotherapeutics. It is suggested that the systematization of nursing care is present in health institutions, and that institutional protocols are developed to facilitate the professional nursing practice in immunotherapy.
References
Abdel-Rahman, O., Eltobgy, M., Oweira, H., Giryes, A., Tekbas, A., & Decker, M. (2017). Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review. Immunotherapy, 9(14), 1175-1183.
American Cancer Society. (2020). CAR T-cell therapy and its side effects. Atlanta: ACS.
Bartell, H., Wolchok, J., Hodi, F. S., Liu, H., Wojtaszek, C., & Weber, J. (2015). Immuno-oncology safety education experience: key lessons from ipilimumab (IPI). Journal for ImmunoTherapy of Cancer, 3(Suppl 2), P384.
Becze, E. (2015). Immunotherapy experts identify key oncology nursing priorities ons summit. Pittsburgh: ONS VOICE.
Becze, E. (2016). An oncology nursing overview of new immune checkpoint inhibitors. Pittsburgh: ONS VOICE.
Brasil. (2019). Estimativa 2020: incidência de câncer no Brasil. Rio de Janeiro: INCA.
Brasil. (2020). ABC do câncer: abordagens básicas para o controle do câncer. Rio de Janeiro: INCA.
Bruneto, R. V., Arruda, G. N., Fernandes, K. T., Pacca, F. C., & Veiga, T. (2019). Anticorpos monoclonais no tratamento oncológico: revisão de literatura para o atendimento ao paciente e manejo das reações infusionais. Archives of Health Sciences, 26(3), 173-178.
Bulechek, G. (2011). Classificação das Intervenções de Enfermagem (NIC). Amsterdã: Elsevier Health Sciences.
The Joanna Briggs Institute. (2015). The Joanna Briggs Institute Reviewers’ Manual 2015: Methodology for JBI Scoping Reviews. Adelaide: JBI.
Cordeiro, M. L. S., Silva, N. L. F., Vaz, M. R. F., & Nóbrega, F. F. F. (2014). Anticorpos monoclonais: implicações terapêuticas no câncer. Revista Saúde & Ciência Online, 3(3), 253-265.
Davies, M., & Duffield, E. (2020). Durvalumab immunotherapy: nursing management of immune-related adverse events during the journey of patients with stage III non-small cell lung cancer. Clinical Journal of Oncology Nursing, 24(3), 277-283.
Franco, A. O., & Natal, S. L.(2018). Eventos adversos imunorrelacionados e seu manejo na imunoterapia em pacientes oncológicos. Revista Oswaldo Cruz, 5(19).
Galioto, M., & Mucenski, J. (2019). Immunotherapy summit: proceedings and identified priorities for safe administration and care. Clinical Journal of Oncology Nursing, 23(3), E60-E65.
Gallegos, R., Kogelman, A., Wagner, M., Cloud, A., Olson, M., Robideau, K., Patrick, L., Comfort, J., & Hirko, K. (2019). Chemotherapy Education: an interprofessional approach to standardizing processes and improving nurse and patient satisfaction. Clinical Journal of Oncology Nursing, 23(3), 309-314.
Garrett, N. F. M. S. (2019). Prevalência de toxicidades dermatológicas em pacientes com câncer submetidos ao tratamento com imunoterápicos: revisão sistemática e metanálise. Dissertação de Mestrado, Universidade de Brasília, Brasília, DF, Brasil.
Gordon, R., Kasler, M. K., Stasi, K., Shames, Y., Errante, M., Ciccolini, K., Lucas, A. S., Raasch, P., & Fischer-Cartlidge, E. (2017). Checkpoint inhibitors: common immune - related toxicities. Clinical Journal of Oncology Nursing, 21(2 Suppl), 45-52.
Helber, H. A., Hada, A. L., Pio, R. B., Moraes, P. H. Z., & Gomes, D. B. D. (2018). Immunotherapy-induced pneumonitis: cases report. Jornal Einstein (Sao Paulo), 16(2), eRC4030.
Madden, K. M., & Hoffner, B. (2017). Ipillimumab-Based therapy: consensus statement from the faculty of the melanoma nursing initiative on managing adverse events with ipilimumab and combination therapy with nivolumab. Clinical Journal of Oncology Nursing, 21(4 Suppl), 30-41.
Moretto, I. G., Contim, C. L. V., & Santo, F. H. E. (2019). Acompanhamento por telefone como intervenção de enfermagem a pacientes em quimioterapia ambulatorial. Revista Gaúcha de Enfermagem, 40, e20190039.
Oliveira, P. P., Bezerril, M. S., Paiva, R. M., Santos, V. E. P., Andrade, F. B., & Silveira, E. A. A. (2019). Segurança do paciente na administração de quimioterapia antineoplásica e imunoterápicos para tratamento oncológico: scoping review. Revista Texto & Contexto - Enfermagem, 28, 1-18.
Orue, I. T., Hernández, A. I. J., & Garcet, M. A. C. (2007). Experiencia de enfermería en la inmunoterapia con gangliósidos en pacientes con cáncer avanzado. Revista Cubana de Enfermagem, 23(3), 1-8.
Rubin, K. M. (2015). Understanding immune checkpoin inhibitors for effective patient care. Clinical Journal of Oncology Nursing, 19(6), 709-717.
Seery, V. (2017). Interprofessional collaboration with immune checkpoint inhibitor therapy: the roles of gastroenterology, endocrinology and neurology. Seminars in Oncology Nursing, 33(4), 402-414.
Serra, J., Majem, M., Sullivan, I. G., Riudavets, M., Anguera, G., Barba, A., González, I., & Guàrdia, N. (2019). P1.07-09 implementation of a nursing program for cancer patients treated with immunotherapy by an Immunotherapy Nurse Specialist. Journal of Thoracic Oncology, 14(10), S490-S491.
Sheldon, L. K. (2016). Oncology nurses and the cancer moonshot 2020. Clinical Journal of Oncology Nursing, 20(4), 355-356.
Silvestrini, A. A. (2020). Diretrizes oncológicas (3a ed). [S.l]: Diretrizes Oncológicas.
Sociedade Brasileira de Farmacêuticos em Oncologia & Agência Nacional de Vigilância Sanitária. (2011). Guia para Notificação de Reações Adversas em Oncologia (2a ed). São Paulo: SOBRAFO/ ANVISA. Recuperado em 10 agosto, 2020 de https://sobrafo.org.br/wp-content/uploads/2018/12/ATT00373.pdf
Thomas R. (2016). Understanding immunotherapy for the treatment of non-small cell lung cancer. Brazilian Journal of Nursing, 25(16), S12-s17.
Tolentino, G. S., Bettencourt, A. R. C., & Fonseca, S. M. (2019). Construction and validation of an instrument for nursing consultation in outpatient chemotherapy. Revista Brasileira de Enfermagem, 72(2), 391-399.
Vazquez, A. (2017). Hypophysitis Nursing management of immune-related adverse events. Clinical Journal of Oncology Nursing, 21(2), 154-156.
Wainstein, A. J., Calabrich, A., Melo, A. C., Buzaid, A. C., Katz, A., Anjos, C. A., Ferreira, C. G., Baldotto, C., Mathias, C. M. C., Yen, C. T., Sternberg, C., E. Gomes, E., Moura, F., Castro Junior, G., Fernandes, G. S., Hoff, P. M. G., Schmerling, R., Munhoz, R. R., Barroso-Sousa, R., Azevedo, S. J., & Lima, V. C. C. (2017). Diretrizes brasileiras de manejo de toxicidades imunomediadas associadas ao uso de bloqueadores de correceptores imunes. Brazilian Journal of Oncology, 13(43), 1-15.
Wiley, K., Lefebvre, K. B., Wall, L., Baldwin-Medsker, A., Nguyen, K., Marsh, L., & Baniewicz, D. (2017). Immunotherapy administration: oncology nursing society recommendations. Clinical Journal of Oncology Nursing, 21(2), 2-7.
World Health Organization. (2020). WHO report on cancer: setting priorities, investing wisely and providing care for all care for all. Geneva: WHO.
Ysebaert, L., Larcher, M., Compaci, G., Oberic, L., Sahnes, L., Banos, A., Araujo, C., Sommet, A., Laurent, G., & Despas, F. (2019). Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia. Annals of Hematology, 98(4), 931-939.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Isabelle Cristine Tavares Silva Fialho; Débora Esteves Monteiro; Raquel de Souza Soares; Renata Martins Mendes de Oliveira; Patrícia dos Santos Claro Fuly
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
